CONTRACT's Questionnaire to Analyse and Improve Informed Consent in Clinical Trials

In the frame of the European Project CONTRACT, which aims at analysing, improving and harmonising "informed consent" across Europe a questionnaire has been set up which will analyse the current situation concerning the legal, ethical, technical and clinical handling of consent, mainly in European projects dealing with vulnerable patient groups. The purpose is to identify existing practices and problems encountered in translational research throughout Europe.

By participating in this survey you will help us to advise translational research projects in all issues of informed consent and to deliver concretepolicy recommendations as to how the European Union could jointly protect patient's rights and support translational research by a better structured approach towards consent issues. The survey is addressed to:

  • Clinicians/Care providers,
  • Chairpersons of research projects/trials,
  • Researchers/Molecular biologists,
  • Computer Scientists,
  • Legal Experts/Ethicists,
  • Data Manager/Statisticians,
  • European Policymakers.

In addition you will gain access to the advisory service via the helpdesk provided by CONTRACT, please visit www.contract-fp7.eu for further details.

CONTRACT's electronic survey is now accessible online under the following link::
https://contract.custodix.com/index.php?sid=67123&lang=en

About CONTRACT Project
The CONTRACT project is a two-year support action (2010-2012) funded under the Health theme of the EU's Framework Programme 7.

CONTRACT seeks to establish methods to understand the way the European Data Protection Directive and the Clinical Trials Directive have had and continue to have an impact on the success of translational research. The project will focus on informed consent as a fundamental precondition for the legal processing of personal data and for carrying out a legally admissible trial.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...